Dr Roskrow must be excited as she has noted in the last two announcements (which are four days apart) "that Patrys has recently commenced a collaboration program with a global biotechnology company to genetically engineer T cells".
I recall she was excited on the second of April this year when she informed us that data on the production of PAT-SM6 in an easy-to-grow plant manufacturing system have been published in the leading peer-reviewed journal Proceedings of the National Academy of Sciences (PNAS). Which led her to make this statement in the report " We are very excited that our lead product, PAT-SM6, is once again at the forefront of new discoveries and the results of this collaboration prove that the IgM class of antibodies, that Patrys is focused on, can become the immunotherapy of choice in the near future" . No mention in the Preliminary Final Report which means she must be really excited about genetically engineering T cells to have forgotten about Nicotiana Benthamiana.
As Dr Roskrow has been in the CEO's chair since June 2011 I really do think it is about time she has cut an out-licensing deal for PAT-SC1 and get excited about bringing some money into the business.
Write your reply here
(20min delay)